阿司匹林联合替格瑞洛治疗急性心肌梗死的 临床疗效及安全性分析

The clinical efficacy and safety analysis of aspirincombined with ticagrelor in the treatment of acutemyocardial infarction

目的研究阿司匹林联合替格瑞洛治疗急性心肌梗死的临床效果和安全性。方法选取2018年1月至2019年2月本院收治的86例急性心肌梗死患者,根据治疗方法的不同分成观察组和对照组,每组43例。观察组采用阿司匹林联合替格瑞洛治疗,对照组采用阿司匹林联合氯吡格雷治疗。比较两组患者心血管事件(MACE)、出血事件发生情况及治疗1周、1个月、6个月后左心室射血(LVEF)分数。结果观察组MACE发生率为6.98%,低于对照组的23.26%,差异有统计学意义(P<0.05);治疗1周、1个月、6个月后,观察组LVEF分数均高于对照组,差异有统计学意义(P<0.05)。两组出血事件发生率比较差异无统计学意义。结论阿司匹林联合替格瑞洛治疗急性心肌梗死能有效减少MACE和出血事件,改善病情,值得临床推广应用。

Objective To study the clinical effect and safety of aspirin combined with ticagrelor in the treatment of acute myocardial infarction.Methods 86 patients with acute myocardial infarction admitted to our hospital from January 2018 to February 2019 were selected and divided into observation group and control group according to different treatment methods,with 43 cases in each group.The observation group was treated with aspirin combined with ticagrelor,and the control group was treated with aspirin combined with clopidogrel.The incidence of cardiovascular events(MACE),bleeding events,and left ventricular ejection(LVEF)scores after 1 week,1 month,and 6 months of treatment were compared between the two groups.Results The incidence of MACE in the observation group was 6.98%was lower than that of the control group of 23.26%,the difference was statistically significant(P<0.05).After 1 week,1 month and 6 months of treatment,the score of LVEF in the observation group were higher than that in the control group,the difference was statistically significant(P<0.05).There was no statistically significant difference in the incidence of bleeding events between the two groups.Conclusion Aspirin combined with ticagrelor in the treatment of acute myocardial infarction can effec-tively reduce the occurrence of MACE and bleeding events and improve the condition,and it is worthy of clinical application.